Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393465 · ClinicalTrials.gov registry record
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
A clinical trial of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), sponsored by Pfizer.
- Active
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06393465 is a study of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06393465, a study of Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
Conditions Studied
Interventions
- DRUG Tafamidis
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-06-15 |
| Est. Completion | 2026-02-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06393465
The ClinicalTrials.gov registry entry for NCT06393465 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) appearing as the primary indexed condition, and to 1 intervention - of which Tafamidis is the first listed.
NCT06393465 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06393465 about?
NCT06393465 is a clinical study titled "Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy". This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
What is the current status of trial NCT06393465?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2024-06-15. Estimated completion is 2026-02-20.
What conditions does trial NCT06393465 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
What interventions are being tested in trial NCT06393465?
The interventions under investigation include: Tafamidis (DRUG).
Who is sponsoring clinical trial NCT06393465?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06393465 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.